The deputy general manager of this pharmaceutical company left! In the first three quarters, the company had 4 key R&D projects approved for clinical trials

【Pharmaceutical Network Industry News】On November 16, Sinovac Pharmaceutical announced that Ms.
Shi Weijin, the company's deputy general manager, applied to resign as the company's deputy general manager due to personal reasons, and will no longer hold any position
in the company after resignation 。 According to the data, Sinovac Biotech is an innovative international biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein drugs and microecological preparations, focusing on antiviral, tumor and immunology, blood, digestion, degenerative diseases and other therapeutic fields, focusing on new proteins, new antibodies, nucleic acid drugs and other technical directions, through the "innovation + overseas commercialization" two-wheel driven platform development model, with biotechnology to serve global patients
.
R&D and innovation are an important driving force for the sustainable development of
pharmaceutical enterprises.
The company pays attention to R&D investment, and in the first three quarters of this year, R&D investment increased by 63.
46% year-on-year, reaching 124 million, which has exceeded the 123 million yuan
in 2021.
With continuous R&D investment, the company's R&D pipeline has steadily advanced
.
In the first three quarters of this year, Sinovac Pharmaceutical received clinical applications for 5 key R&D projects by the State Medical Products Administration, including SHEN26 capsules, pegylated human granulocyte stimulating factor injection, human interferon α2b effervescent capsules and human interferon α2b spray, and other 4 projects have obtained the "Drug Clinical Trial Approval Notice
".
Among them, the SHEN26 capsule project is carrying out phase I clinical trial related work, and the patient enrollment work is expected to be completed
in the fourth quarter of this year.
Recently, the company also announced that its human interferon α1b inhalation solution was approved for clinical trials for pediatric respiratory syncytial virus lower respiratory tract infection (pneumonia, bronchiolitis).

The announcement said that the product is another major breakthrough in the field of antiviral for the company, the drug is a special drug for children, through atomized administration, the active ingredient can directly reach the lesion, faster onset, compared with injection, children do not need to bear the pain of injection, acceptance and safety are higher
.
High R&D investment, coupled with rising labor costs and sales expenses, the company's performance is in a declining stage
.
According to the third quarterly report of 2022, the main revenue reached 944 million yuan, a year-on-year increase of 5.
33%; net profit attributable to the parent - 56.
7192 million yuan, down 175.
31% from the same period last year; Deduction of non-net profit - 59.
3722 million yuan, down 190.
85% from the same period last year; Among them, in Q3, the company achieved main revenue of 315 million yuan, a year-on-year increase of 4.
6%; net profit attributable to the parent - 59.
6168 million yuan, down 509.
4% from the same period last year; The non-net profit in a single quarter was -62.
7528 million yuan, down 608.
86%
from the same period last year.
However, the company's overseas market performance is good, and the overseas sales revenue in the first three quarters increased by 65.
84%
year-on-year.
It is understood that the company actively deploys internationalization, and from 2021 began to introduce a number of blockbuster high-end generic drug products to promote overseas commercialization, including albumin paclitaxel, infliximab, bevacizumab, etc.
, and the disease field covers tumor and immunity
。 According to the company's disclosure, as of the third quarter, Baizi has been accepted by the State Food and Drug Administration and the European Medicines Agency, and is fully promoting the construction of production lines; Infliximab completed the submission of drug registration documents to 17 overseas countries, and achieved online sales in 32 provinces in China, covering more than 360 hospitals; Bevacizumab has also entered the stage from technical review to submission of registration materials, and has started product registration in 14 countries, accelerating overseas commercialization; In addition, the company signed the "Adalimumab Overseas Market Exclusive License Cooperation Agreement" with Hisun Biologics, and the initial signing cooperation area covers 7 countries
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.